Skip to main content
. 2022 Sep 14;11(18):e026075. doi: 10.1161/JAHA.122.026075

Figure 1. Methods for simulated PCSK9i and IPE eligibility assuming maximal escalation of lipid‐lowering therapy.

Figure 1

HDL‐C indicates high‐density lipoprotein cholesterol; IPE, icosapent ethyl; LDL‐C, low‐density lipoprotein cholesterol; PCSK9i, proprotein convertase subtilisin kexin type 9 inhibitor; and Rx, prescription.